Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7183282 | INTRA-CELLULAR | Substituted heterocycle fused γ-carbolines |
Jun, 2020
(3 years ago) | |
USRE39680 | INTRA-CELLULAR | Substituted heterocycle fused gamma-carbolines |
Jun, 2020
(3 years ago) | |
USRE48825 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(4 years from now) | |
US9586960 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(4 years from now) | |
US8648077 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(3 years from now) | |
US9199995 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(4 years from now) | |
US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(5 years from now) | |
US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(5 years from now) | |
US9168258 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(5 years from now) | |
US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(5 years from now) | |
USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(9 years from now) | |
US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(10 years from now) | |
US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(10 years from now) | |
US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(10 years from now) | |
US11806348 | INTRA-CELLULAR | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
US11052084 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
US11690842 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
US11753419 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(16 years from now) |
Caplyta is owned by Intra-Cellular.
Caplyta contains Lumateperone Tosylate.
Caplyta has a total of 20 drug patents out of which 2 drug patents have expired.
Expired drug patents of Caplyta are:
Caplyta was authorised for market use on 22 April, 2022.
Caplyta is available in capsule;oral dosage forms.
Caplyta can be used as treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways, treatment of bipolar depression, treatment of schizophrenia with improvement in residual symptoms of schizophrenia, treatment of bipolar disorder i, bipolar disorder ii, or bipolar depression, modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia, treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways, treatment of schizophrenia.
Drug patent challenges can be filed against Caplyta from 21 December, 2023.
The generics of Caplyta are possible to be released after 10 December, 2040.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
New Indication(I-882) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of bipolar disorder i, bipolar disorder ii, or bipolar de...
Dosage: CAPSULE;ORAL